Nachrichten zur Neurocrine Biosciences Aktie

BB Biotech: Top-Beteiligungen Vertex und Neurocrine - das ist einfach stark!

Die Aktie der Schweizer Beteiligungsgesellschaft BB Biotech hat zuletzt wieder Schwung aufgenommen und notiert nur noch knapp unterhalb des Dezemberhochs…

How Neurocrine Biosciences Crushed It in Q4

The biotech trounced Wall Street revenue and earnings estimates thanks to strong sales for its tardive dyskinesia drug....…

Neurocrine Biosciences Inc (NBIX) Q4 2019 Earnings Call Transcript

NBIX earnings call for the period ending December 31, 2019....…

Neurocrine Biosciences, Inc. (NBIX) CEO Kevin Gorman on Q4 2019 Results - Earnings Call Transcript

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Neurocrine Biosciences (NBIX) Q4 Earnings Lag Estimates

Neurocrine (NBIX) delivered earnings and revenue surprises of -57.32% and 0.71%, respectively, for the quarter ended December 2019. Do the…

Neurocrine Biosciences, Inc. 2019 Q4 - Results - Earnings Call Presentation

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Q4 sales of Neurocrines Ingrezza up 83%

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Neurocrine Biosciences Reports Fourth Quarter and Full-Year 2019 Financial Results

SAN DIEGO , Feb. 4, 2020 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced…

Neurocrine Biosciences Announces Appointment of Shalini Sharp to Board of Directors

SAN DIEGO , Feb. 3, 2020 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today…

Neurocrine Biosciences Announces Conference Call and Webcast of Fourth Quarter and Year-End 2019 Financial Results

SAN DIEGO , Jan. 20, 2020 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced…

Zacks.com featured highlights include: Zumiez, Neurocrine Biosciences and Covanta

Zacks.com featured highlights include: Zumiez, Neurocrine Biosciences and Covanta...…

Neurocrine Knocked Back On Ingrezza Concerns And Maybe The Lack Of A Buyout

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Neurocrine Biosciences (NBIX) Presents At 38th Annual J.P. Morgan Healthcare Conference - Slideshow

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Neurocrine Bio expects $238M in Q4 Ingrezza sales

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Neurocrine Biosciences Provides Preliminary Fourth Quarter and Full-Year 2019 Net Product Sales Results and 2020 Program Milestones

SAN DIEGO , Jan. 12, 2020 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today provided…

Idorsia pairs with Neurocrine in potential $400 mln epilepsy drug deal

Swiss biotech group Idorsia on Friday lifted the lid off a 2019 deal for its investigational epilepsy medicine, revealing the pact that…

Lizenzvereinbarung - Idorsia winkt Zahlung von amerikanischer Partnerfirma

Das Biotechunternehmen Idorsia könnte im Rahmen einer Lizenzvereinbarung von seinem US-Partner Neurocrine Biosciences eine Vorauszahlung von 45 Millionen US-Dollar erhalten....…

Neurocrine Biosciences and Idorsia amend option agreement to license novel treatment for rare pediatric epilepsy

SAN DIEGO, U.S. and ALLSCHWIL, Switzerland - January 10, 2020Neurocrine Biosciences, Inc. (NASDAQ: NBIX) and Idorsia Ltd. (SIX: IDIA) announced…

Will Neurocrine (NBIX) Beat Estimates Again in Its Next Earnings Report-

Neurocrine (NBIX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for…

Why Neurocrine Biosciences Soared 50.5% in 2019

Rapid sales growth for its tardive dyskinesia drug fueled investor optimism....…

Neurocrine Biosciences to Present at the 38th Annual J.P. Morgan Healthcare Conference Live Audio Webcast will be on January 13, 2020

SAN DIEGO , Jan. 6, 2020 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) will present…

Aurelius bearish on Neurocrine Biosciences

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Neurocrine Partners With Xenon To Add New Early-Stage Pipeline Assets

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Xenon Pharma up 23% premarket on Neurocrine Bio partnership in epilepsy

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Xenon Pharmaceuticals to Host Conference Call and Webcast to Provide Corporate Update on License and Collaboration Agreement with Neurocrine Biosciences

BURNABY, British Columbia, Dec. 02, 2019 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, announced…

Neurocrine Biosciences and Xenon Pharmaceuticals Announce Agreement to Develop First-in-Class Treatments for Epilepsy

Neurocrine Biosciences Gains Rights to XEN901, a Clinical Stage Selective Nav1.6 Sodium Channel Inhibitor, Being Developed for the Treatment of…

Neurocrine Biosciences and Xenon Pharmaceuticals Announce Agreement to Develop First-in-Class Treatments for Epilepsy

SAN DIEGO and BURNABY, British Columbia , Dec. 2, 2019 …

Neurocrine Biosciences to Present at Evercore ISI 2nd Annual HealthCONx Conference

SAN DIEGO , Nov. 26, 2019 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) will present…

Neurocrine Making The Most Of A Strong Ingrezza Launch

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Neurocrine Bounces Back With Authority, But Little Upside Appears Evident As New Year Approaches

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Neurocrine Biosciences, Inc. 2019 Q3 - Results - Earnings Call Presentation

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Neurocrine Biosciences, Inc. (NBIX) CEO Kevin Gorman on Q3 2019 Results - Earnings Call Transcript

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Neurocrine Biosciences Inc (NBIX) Q3 2019 Earnings Call Transcript

NBIX earnings call for the period ending September 30, 2019....…

Neurocrine Biosciences (NBIX) Beats Q3 Earnings and Revenue Estimates

Neurocrine (NBIX) delivered earnings and revenue surprises of 19.70% and 5.16%, respectively, for the quarter ended September 2019. Do the…

Neurocrine Biosciences EPS misses by $0.09, beats on revenue

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2019 Financial Results

SAN DIEGO , Oct. 14, 2019 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced…

Neurocrine Biosciences Presents New Data Analyses Demonstrating Long-Term Effects of INGREZZA® (valbenazine) 40 mg Once-Daily in Patients with Tardive Dyskinesia at the 2019 Annual Psych Congress

SAN DIEGO , Oct. 4, 2019 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today…

Neurocrine Biosciences to Present Data Analyses Demonstrating the Long-Term Effectiveness of INGREZZA® (valbenazine) in Patients with Tardive Dyskinesia at the 2019 Annual Psych Congress

SAN DIEGO , Oct. 1, 2019 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced…

AbbVie Submits New Drug Application to US FDA for Investigational Elagolix for Management of Heavy Menstrual Bleeding Associated with Uterine Fibroids in Women

NORTH CHICAGO, Ill. , Aug. 5, 2019 /PRNewswire/ -- AbbVie (NYSE: ABBV), a research-based global…